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Abstract
In a classical dogma, pathogens are sensed (via recognition of Pathogen Associated Molecular Patterns (PAMPs)) by innate
immune cells that in turn activate adaptive immune cells. However, recent data showed that TLRs (Toll Like Receptors), the
most characterized class of Pattern Recognition Receptors, are also expressed by adaptive immune B cells. B cells play an
important role in protective immunity essentially by differentiating into antibody-secreting cells (ASC). This differentiation
requires at least two signals: the recognition of an antigen by the B cell specific receptor (BCR) and a T cell co-stimulatory
signal provided mainly by CD154/CD40L acting on CD40. In order to better understand interactions of innate and adaptive B
cell stimulatory signals, we evaluated the outcome of combinations of TLRs, BCR and/or CD40 stimulation. For this purpose,
mouse spleen B cells were activated with synthetic TLR agonists, recombinant mouse CD40L and agonist anti-BCR
antibodies. As expected, TLR agonists induced mouse B cell proliferation and activation or differentiation into ASC.
Interestingly, addition of CD40 signal to TLR agonists stimulated either B cell proliferation and activation (TLR3, TLR4, and
TLR9) or differentiation into ASC (TLR1/2, TLR2/6, TLR4 and TLR7). Addition of a BCR signal to CD40L and either TLR3 or TLR9
agonists did not induce differentiation into ASC, which could be interpreted as an entrance into the memory pathway. In
conclusion, our results suggest that PAMPs synergize with signals from adaptive immunity to regulate B lymphocyte fate
during humoral immune response.
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Introduction
Immune response activation by pathogens involves various
receptors, known as pattern recognition receptors (PRRs) that
recognize pathogen-specific molecular patterns (PAMP for ‘‘Path-
ogen Associated Molecular Pattern’’) (reviewed in [1]). Among the
seven classes of PRRs, the best characterized class is Toll-Like
Receptors (TLRs), a family of type I transmembrane proteins
characterized by highly divergent leucine-rich extracellular domains
and highly conserved Toll-IL-1R cytoplasmic domains. To date, 11
mouse and human TLRs have been described allowing detection of
specific pathogen markers that included lipopolysaccharide (LPS),
double-standed RNA, peptidoglycan and hypomethylated DNA
(reviewed in [2]). Most TLRs (TLR 1, 2, 4, 5, 6, 10 and 11) are
expressed on the cell surface, whereas others TLRs (TLR 3, 7, 8 and
9) are present in endosomal compartments. Furthermore, TLRs are
expressed as homodimers or as heterodimers (TLR1+TLR2 or
TLR2+TLR6). Finally, TLRs are linked by adapter molecules
(MyD88 or TRIF) to intracellular signaling pathways that generally
lead to transcription of NF-kB and IRF target genes.
Pathogen recognition by PRRs activates innate immune cell,
including dendritic cells that can in turn activate the adaptive
immune response. Moreover, many reports described that TLR
expression on lymphocytes allowed direct activation of adaptive
immune responses by PAMPs, such as B cell activation and
differentiation into antibody secreting cells (ASC). It was described
years ago that activation of the TLR4 pathway by LPS triggers
mouse B cell proliferation, differentiation into ASC and isotype
switch [3]. More recently, using mice deficient for MyD88, Pasare
et al. [4] showed that direct TLR-signal is essential for B cell
activation and differentiation into ASC. These results were
opposed by Gavin et al. [5] who showed, by using mice deficient
in both MyD88 and TRIF, that direct-TLR signal was not
necessary for B cell activation and differentiation. Finally, Meyer-
Bahlburg et al. [6] showed that B-cell intrinsic TLR signals
amplified but were not required for humoral immunity. In the
same way, various in vitro assays using mouse B cells showed that
TLR1/2 or 2/6 [7–11], TLR3 [12], TLR4 [7–8,10], TLR7 [13–
14], TLR8 [15] and TLR9 [7–8,10] agonists induced B cell
proliferation, expression of activation markers and cytokine
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production while TLR2 [7–10], TLR4 [8,10], TLR7 [8,10] and
TLR9 [8,10] agonists induced B cell differentiation into ASC. Of
note, TLR5 expression on mouse B cells is still controversial and B
cell activation or differentiation by TLR5 agonists has never been
described [8,10]. Similarly, various reports have led to the
conclusion that mouse TLR8 is nonfunctional [16–17]. More
recently, TLR8 has been described as a negative regulator of
TLR7-induced immune response [18].
Beside these newly described innate stimuli, the current dogma
postulates that 2 signals are necessary to drive T-dependent naive
B cell proliferation and differentiation into ASC: recognition of an
antigen by the B cell-specific receptor (BCR) and a T cell co-
stimulatory signal in which CD40L (CD154) expressed on
activated T cells activates CD40 on B cells. Interaction of CD40
with CD154 is essential for antibody production and isotype switch,
and therefore for an optimal humoral immune response. Moreover,
various studies showed that dual stimulation of B cells through BCR
and CD40 leads to an enhancement of antibody and cytokine
production (reviewed in [19–20]). However, the effects and
mechanisms of interactions between innate immune receptors and
BCR or CD40 are not yet well defined. Some reports showed that
addition of CD40 signal to TLR7 or TLR9 agonists enhanced
cytokine production [21–22] as well as B cell differentiation into
ASC [22–23] in both human and mouse primary B cells. These
effects were increased after addition of a BCR signal. In contrast,
Kno¨del et al. [24] showed that although TLR4 agonists synergize
with CD40L to induce plasma cell differentiation, addition of BCR
signal results in suppression of B cell differentiation into ASC.
B cells play an important role in protective immunity [25] as
producers of both antibodies and cytokines. Activation of naive B
cells results in expression of activation marker (such as CD69 and
CD86), production of cytokines (for example CCL22 [26]) and
proliferation. Among proliferating cells, some differentiate into
ASC and others into memory B cells. Some cells migrate to
germinal centers to finish their differentiation and produce highly
efficient neutralizing antibodies. To this end, the affinity
maturation of antibody response is required and involves
immunoglobulin class switch recombination (CSR) that directs
antibody production from IgM to IgG, IgA and IgE and somatic
hypermutation (SHM) that modifies the Ig variable region gene to
obtain BCR with high affinity for antigen. Both events are
controlled by the activation-induced cytidine deaminase (AID)
(Reviewed in [27]). CD138 (Syndecan-1), a proteoglycan that
recognizes extracellular matrix and growth factors, is present on
ASC and is often used as marker of plasma cells [28]. However, as
CD138 is also expressed on plasmablasts [29] prior to the fully
differentiated plasma cells, ASC are characterized not only by a
high expression of CD138 but also by a low expression of B220
molecule [30]. Differentiation to ASC correlates with the
expression of a number of transcription factors among which B
lymphocyte-induced maturation protein 1 (Blimp-1) has been
proposed to be the master regulator [31]. Conversely, the
transcription factor Pax5 is associated with the mature B cell
phenotype and downregulated in ASC [32].
Here, we systematically screened the effects of combined
activation of TLRs, CD40 or the BCR on B cell proliferation,
activation and differentiation into ASC. To this end, mouse spleen
B cells were activated by different TLR agonists alone or in the
presence of recombinant mouse CD40L and/or anti-BCR
antibodies to mimic antigen. As expected, mouse B cells stimulated
with TLR agonists were activated, proliferated and differentiated
into ASC. Nevertheless, differentiation to ASC was not observed
for TLR3 and TLR9 agonists. Addition of a CD40 signal to TLR-
stimulated B cells induced either increased B cell proliferation and
activation (TLR3, TLR4, and TLR9) or increased B cell
differentiation into ASC (TLR1/2, TLR2/6, TLR4 and TLR7).
Furthermore, differentiation into ASC was not increased by
addition of BCR signal after stimulation of CD40 and TLR3 or
TLR9.
Taken together, our results suggest that signals originating
directly from pathogens interact with signals from adaptive
immunity to regulate B lymphocyte fate during humoral immune
responses.
Results
TLR-3, -4 and -9 but not TLR -1/2, -2/6 and -7 agonists
synergize with CD40L to increase mouse spleen B cell
proliferation and activation
To evaluate the effect of dual B cell stimulation by both innate
and adaptive immune signals on cell proliferation/survival and
activation, mouse spleen B cells were cultured in the presence of
increasing concentration of TLR and CD40 agonists. [3H]thymi-
dine incorporation, cell surface expression of CD69 and CD86,
and CCL22 production (the first cytokine produced during B cell
activation [26]) were measured. TLR2/6 pathway was activated
by Pam2CSK4, TLR1/2 by Pam3CSK4, TLR3 by poly (I:C),
TLR4 by lipopolysaccharide (LPS), TLR7 by R848 and TLR9 by
unmethymated CpG oligodeoxynucleotides type C (ODN 2395
described to activate B and dendritic cells [33]). CD40 pathway
was activated by recombinant mouse CD40L (mCD40L).
As expected, our data indicated that, in the absence of
mCD40L, agonists of TLR 1/2, 2/6, 4 and 7 but not agonists of
TLR3 and TLR9 induced strong mouse B cell proliferation
(Figure 1). Although mCD40L alone induced only a slight
proliferative response (Figure 1, white bars), addition of
mCD40L to TLR3 (Figure 1C), TLR4 (Figure 1D) and TLR9
(Figure 1F) agonists induced an increase in mouse B cell
proliferative response. In contrast, mCD40L addition had no
significant effect on TLR1/2- (Figure 1A), - TLR2/6 (Figure 1B)
and TLR7- (Figure 1E) induced B cell proliferative response. The
specificity of mCD40L action was confirmed in CD40-deficient
splenic B cells (Figure S1A). Moreover, Polymixin B, an inhibitor
of LPS activity inhibited LPS-induced proliferative response with or
without mCD40L addition but had no effect on TLR3-induced
proliferation as well as on the increase of this proliferative response
in the presence of mCD40L (Figure S1B), showing the specificity
of each TLR agonist and ruling out the possibility of a mCD40L-
independent LPS-dependent B cell proliferation.
The proliferative response measured by thymidine uptake
quantifies not only the activity of dividing cells but also the
survival rate of proliferating cells. CD40L is known to promote
both proliferation and survival, although we didn’t attempt to
distinguish both effects in this study. In CFSE labeling exper-
iments, an increase in cell survival as well as in the numbers of
dividing cells was observed in the conditions in which an increase
of thymidine uptake was observed (Data not shown).
B cell activation induced by TLR agonists and mCD40L was
evaluated by monitoring CD69 and CD86 surface expression as
well as CCL22 production. As expected, all TLR agonists tested
taken alone increased activation marker expression (CD69;
Figure 2A or CD86; Figure 2B). Only a fraction of B cells
increased CD69 expression (from 10% in non treated cells to 85%
in fully activated cells) whereas all B cells increased CD86
expression. Production of CCL22, was increased after activation
by TLR3 and TLR4 agonists alone (Figure 2C). As seen for the
proliferative response, co-treatment with mCD40L increased
CD69 (Figure 2A) and CD86 (Figure 2B) expression as well
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as in CCL22 production (Figure 2C) in response to TLR3 and
TLR4 agonists and to a lower extent to TLR9 agonist, but no or
little to TLR1/2, TLR2/6 and TLR7 agonists. As for proliferative
response, mCD40L alone only slightly increased activation marker
expression and CCL22 production (Figure 2).
In conclusion, our data demonstrate that the CD40 pathway
synergizes with TLR3, 4 and 9 pathways, but not with TLR1, 2, 6
and 7 for B cell proliferative response and activation (Table 1).
TLR -1/2, -2/6, - 4 and -7 but not TLR-3 and -9 agonists
synergize with CD40L to increase mouse spleen B cell
differentiation in plasma cells
We next examined the potential synergy of TLRs and CD40
pathways on antibody production, B cell differentiation into ASC
and affinity maturation of antibody response.
Mouse spleen B cells were co-stimulated with TLR agonists and
mCD40L. Differentiation into ACS was monitored by following
mRNA expression of Blimp-1, the master regulator of ASC
differentiation [31]. As shown in figure 3A, TLR1/2, TLR2/6,
TLR4 and TLR7 agonists induced an increase of Blimp-1 mRNA
expression that is enhanced by addition of mCD40L, indicating
the triggering of the gene programme for ASC differentiation.
Incubation of splenic B cells with mCD40L alone (Figure 3A) did
not increase Blimp-1 mRNA expression. The specificity of
mCD40L action was confirmed in CD40-deficient B cells (Figure
S2A). Similarly, Blimp-1 mRNA expression induced by TLR2 and
TLR4 agonist was inhibited by an antagonist anti-TLR2 antibody
(Figure S2B) and by polymixin B (Figure S2C) respectively,
showing that these TLR pathways are implied in Blimp-1 mRNA
expression induction.
As shown in Figure 3A, TLR3 agonist as well as TLR9 Type C
agonist (ODN 2395), described to activate B and dendritic cells
[33] or TLR9 Type B agonist (ODN 1668, Figure S2D),
described to activate B cells [34] did not induce any increase in
Blimp1 mRNA expression. Addition of mCD40L to these agonists
did not modify Blimp-1 mRNA expression. As it was proposed
that full-blown naive human B cell activation requires three
synergically acting stimuli, TLR engagement, interaction of CD40
with CD40L and recognition of antigen by the B cell specific
receptor (BCR) [35–36], an anti-IgM antibody was added to
engage the BCR in the presence of TLR3 and TLR9 agonists and
mCD40L. As shown in figure 3B, the addition of a BCR signal
did not increase Blimp-1 expression in B cell cultures stimulated
with combinations of mCD40L with TLR3 and TLR9 agonists
(Figure 3B). On the contrary, stimulation with anti-IgM always
decreased Blimp-1 mRNA expression, even with CD40L – TLR4
combinations that induced Blimp-1 when applied alone.
To characterize more precisely the B cell subset expressing
Blimp-1 mRNA, mouse spleen B cells were cultured as described
above and then enriched for CD138+ cells. These cells were tested
for B220 expression by flow cytometry and for Blimp-1, Pax5 and
AID mRNA expression by qRT-PCR. The CD138+ B cell
population contains all plasma cell subsets, including the ASC that
are characterized by low expression of the B220 molecule [30]. To
evaluate the number of ASC, we quantified B220low cells in the
CD138+ population. As showed in figure 4A, all TLR agonists
except TLR3 induced a significant increase in CD138+B220low
cells, corresponding to ASC subpopulation (Figure S4). Addition
of a CD40 signal further increased the number of ASC after
activation of TLR1/2, TLR2/6 and TLR7 pathways. These
Figure 1. Proliferative response of mouse splenic B cells induced by TLR agonists in association with mCD40L. Purified B cells were
stimulated with TLR1/2 agonist (Pam3CSK4) (A), TLR2/6 agonist (Pam2CSK4) (B), TLR3 agonist (Poly (I:C)) (C), TLR4 agonist (LPS) (D), TLR7 agonist
(R848) (E), TLR9 type C agonist (ODN 2395) (F) at the indicated concentrations and in association with increasing concentrations of mCD40L for 72 h.
Proliferation was evaluated by measuring [3H]-thymidine uptake. Data are expressed as mean Stimulation Index (see material and methods) 6 SD of
three independent experiments. The mean of cpm in non activated B cells is 309634. For C, D and F, although addition of mCD40L at all the
concentrations induced significant changes, statistics are only shown for the concentrations used in further experiments (bold letters). *p,0.05,
**p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0025542.g001
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results were corroborated by an increase of Blimp-1 mRNA
expression, characteristic of ASC (Figure S3A), and/or a
decrease of PAX-5 mRNA characteristic of mature B cells
(Figure S3B) in the same conditions.
We next investigated how AID, an enzyme required for CSR and
SHM, was induced at the mRNA level in CD138+ cells. In the
absence of mCD40L, AID mRNA levels was not or minimally
modified by treatment with TLR2/6, TLR3, TLR4 and TLR9
agonists and only slightly increased by treatment with TLR1/2 and
TLR7 agonists (Figure 4B). However, mCD40L increased AID
mRNA expression in CD138+ B cell-enriched population when
added in combinationwithTLR1/2, 2/6, and 7agonists (Figure4B).
Finally, we measured immunoglobulin production in B cell
culture supernatants after 6 days of culture with TLR agonists with
or without mCD40L. Despite poor B cell survival, IgM and IgG
production could be measured in culture supernatants. All TLR
agonists alone induced immunoglobulin production except TLR3
and TLR9 agonists for IgM production (Figure 5A) and TLR3,
TLR7 and TLR9 agonists for IgG production (Figure 5B).
Addition of mCD40L increased IgM production in B cell culture
supernatants after activation by TLR1/2, TLR7 and TLR9
agonists (Figure 5A) and IgG production after activation by
TLR1/2,TLR4 and to a lower extend TLR9 agonists (Figure 5B).
Taken together, these results showed that mCD40L stimulates
differentiation into ASC in vitro, induces AID mRNA expression
and promotes antibody production when combined with TLR1/2,
2/6, 4 and 7 agonists (with the exception of antibody production
induced by TLR2/6) (Table 1).
Figure 2. B cell activation induced by TLR agonists in
association with mCD40L. Purified B cells were cultured with
TLR1/2 agonist Pam3CSK4 (250 ng/mL), TLR2/6 agonist Pam2CSK4
(50 ng/mL), TLR3 agonist poly (I:C) (10 mg/mL), TLR4 agonist LPS (10 mg/
mL), TLR7 agonist R848 (1 mg/mL) or TLR9 agonist ODN 2395 (200 nM)
alone (light gray bars) or in the presence of 0.6 mg/mL mCD40L (dark
gray bars). After 24 h, expression of activation markers CD69 (A) or
CD86 (B) were measured by flow cytometry. Results are expressed as
mean relative fluorescence intensity. Mean values 6 SD of three
independent experiments are shown. (C) CCL22/MDC levels were
measured in cell culture supernatants by ELISA after 48 h. Results are
expressed in pg/mL and represent means 6 SD of three independent
experiments. *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0025542.g002
Table 1. Summary of B cell activation and/or differentiation
induced by TLR agonist in association with mCD40L.
None 1/2 2/6 3 4 7 9
Total B cells Prolif Ns ns ns ++ +++ ns +++
CD69 + ++ ns +++ +++ ++ +++
CD86 Ns ns ns +++ +++ ns +
CCL22 Ns ns ns +++ +++ ns ns
Total BLIMP-1 Ns + ++ ns + + ns
Enriched
CD138+
CD138high
B220low
Ns +++ +++ ns ns +++ ns
AID Ns + ++ ns ns + ns
Total B cells IgM ++ +++ ns + ns +++ +++
IgG Ns +++ ns ns +++ ns +
Results represent the difference between the treatment with TLR agonists alone
in comparison with the co-treatment TLR agonists plus mCD40L. P,0.001 +++,
P,0.01 ++, P,0.05 +, P.0.05 ns.
doi:10.1371/journal.pone.0025542.t001
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Discussion
According to the classical dogma, full-blown naive B cell
activation requires two independent signals: one provided by
recognition of antigen by the specific B cell receptor and another
provided by T-cell co-stimulation via interaction between CD40L
(expressed on activated T cells) and CD40 expressed on B cells.
More recently, the finding that B cells express TLRs and can be
activated by TLR agonists prompted the modification of this
model with a third signal provided directly by pathogens [35] via
Figure 3. Blimp-1 mRNA expression in splenic B cells induced by TLR agonists in association with mCD40L. Purified B cells were
cultured with the indicated TLR agonists (at the concentrations of figure 2) alone (light gray bars) or in the presence of 0.6 mg/mL of mCD40L (dark
gray bar) (A) or with 10 mg/mL of TLR3 agonist poly (I:C), 10 mg/mL of TLR4 agonist LPS or 200 nM of TLR9 agonist ODN 2395 with or without 0.6 mg/
mL of mCD40L and 1 mg/mL anti-IgM antibody, as indicated (B). After 72 h, total RNA was isolated and expression of Blimp-1 transcripts was
evaluated by quantitative real-time PCR. Values were normalized to the mean of expression of three housekeeping genes: GAPDH, b-actin, HPRT.
Results are expressed as the fold induction of gene transcription as compared to purified B cells cultured in medium. Data of one representative
experiment out of three is shown. *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0025542.g003
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binding of PAMPs on PRRs. However, the importance of TLR
signaling in shaping humoral response remains controversial [4–
6]. To evaluate the importance of TLRs in B cell response, authors
immunized mice that were deficient for the signaling of all
(MyD88/TRIF deficient mice [5]) or most (Myd88 deficient mice
[4]) TLRs with model antigens in the presence of various
adjuvants and evaluated antibodies production. In Myd88
deficient mice, Pasare et al. [4] used LPS that binds to TLR4
and have shown a central role for TLR signaling in B cell
response. In Myd88/TRIF deficient mice, Gavin et al. [5] have
used Alum that has been shown later to involve the NOD
(Nucleotide binding domain) Like Receptor (NLR) pathway [37–
38], another family of PRRs, and Freund Complete Adjuvant that
activated TLR2 and TLR4 pathway but also the NLR pathway
via the Muramyl Dipeptide [39] and have, obviously, shown a
poor implication of TLR in antibody production. Moreover, as
dendritic cells also express TLRs [2], the effect of TLR deficiency
on antibody production can be explained by an indirect effect on
DCs. In view of these contradictory results, we tested the direct
role of each TLR on B cell activation and antibody production in
a systematic in vitro assay. Furthermore, as a complete B cell
activation requires at least two signals, we dissociated the various
signals by activating mouse B cell with TLR agonists alone or
associated to the T cell co-stimulation signal CD40L.
As already described [7–13], we confirmed that all TLR
agonists (except those of TLR5 and TLR8 that are not expressed
or not functional or not activating on mouse B cells) induce
proliferation and activation of splenic B lymphocytes (Figure 1
and 2). Surprisingly, the TLR9 agonist type C ODN 2395
described to activate B cell and DC had little effect on B cell
proliferation and activation (Figure 1 and 2). More surprisingly,
we found that the TLR3 agonist poly (I:C) as well as the TLR9
agonist type C (ODN 2395) or type B (ODN 1668) did not induce
B cell differentiation into ASC and antibody production in vitro.
Interestingly, addition of a T cell co-stimulation signal via CD40L
to TLR agonists shows a dissociation between on the one hand,
induction of mouse B cell proliferation and activation and, on the
other hand, induction of B cell differentiation into ASC and
antibody production (Table 1). Indeed, with the exception of the
TLR4 agonist LPS that synergizes with mCD40L to increase both
proliferative response and differentiation into ASC, all other TLR
agonists synergize with mCD40L to increase either a proliferative
response associated with activation marker expression and
cytokine production (TLR3 and TLR9) or B cell differentiation
into ACS and antibody response maturation (TLR 1/2, 2/6 and
7) measured mainly by BLIMP-1 and AID mRNA expression.
The poor survival of plasma cells in vitro made it difficult to analyze
antibody production in cell culture supernatants and this can
explain the discrepancies between Blimp-1 (Figure 3A) and AID
(Figure 4B) mRNA levels and antibody production (Figure 5A
and 5B) when B cells were treated with TLR 2/6 and TLR7
agonists.
Our results offer an explanation for the polyclonal B cell
proliferation and Ig production observed during bacterial and viral
infection [40–44]. Indeed, in 2003, Zinkernagel’s group [44]
showed that hypergammaglobulinemia induced during viral
infection required not only a virus-induced signal but also a T
cell co-stimulation, probably via CD40L. More recently, Soulas
et al. [45], by using MyD88-deficient mice, showed that polyclonal
activation of autoreactive B cells required TLR signal as well as a
co-stimulation signal provided by T cells. However, our results
show that the pathogen via its PAMPs not only synergizes with
activated T cells to induce B cell proliferation and Ig production
but also control B cell response by inducing either a B cell
proliferation and activation that could induce memory B cell
differentiation or production of polyclonal antibodies by bystander
activation. The mechanism explaining this dissociated response is
still unclear. TLR 1, 2, 4 and 6 are expressed on the cell surface,
whereas TLR 3, 7 and 9 are present within the endosomal
compartments. However, this difference in localization cannot
fully account for differences in B cell response as in association
with mCD40L, TLR2 and TLR7 agonists both induce differen-
tiation into ASC. TLR signaling is initiated by four adapters:
Figure 4. B220 expression and AID mRNA expression in CD138-
enriched purified B cell population after activation by TLR
agonists in association with mCD40L. Purified B cells were cultured
with the indicated TLR agonists (at the concentrations of figure 2) alone
(light gray bars) or in the presence of 0.6 mg/mL mCD40L (dark gray
bar). After 72 h, the population was enriched for CD138 positive cells as
described in Material and Methods. (A) CD138-enriched purified B cells
were then co-stained with anti-B220 and anti-CD138 antibodies and the
expression of these markers was determined by flow cytometry. Results
are expressed as % of CD138+ B220low +/2SD of three independent
experiments. (B) Total RNA was isolated and expression of AID
transcripts was evaluated by quantitative real-time PCR. Results are
expressed as the fold induction of gene transcription as compared to
CD138-enriched purified B cells cultured in medium. *p,0.05,
**p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0025542.g004
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MyD88, TRIF (TIR domain-containing adapter inducing inter-
feron beta), TIRAP (TIR domain-containing adapter protein) and
TRAM (TRIF-related adapter molecule). MyD88 associates with
all TLRs except TLR3, whereas TRIF associates with TLR3 and
TLR4. TIRAP and TRAM appear to function as bridging
adapters for MyD88 and TRIF, respectively. TIRAP and TRAM
are essential for signaling by TLR4 and also required for TLR2
function. [46–47] Again, these differences in signaling adapters
alone cannot explain the various B cell responses that we observe.
Finally, we showed that the addition of a BCR signal does not
reorient the activation phenotype induced by TLR3 and TLR9
associated with mCD40L towards differentiation into ASC
(Figure 3B) and even inhibits ASC differentiation induced by
TLR4 in vitro. This effect of BCR signaling has already been
described after activation of mouse B cell by TLR4 agonist
associated with an anti-CD40 antibody and has been interpreted
as the result of memory B cell differentiation [24]. Study of
memory response in vitro is not possible and should be evaluated in
latter in vivo experiments. Alternatively, BCR stimulation could
favor the proliferative response at the expense of a delay in the
differentiation process.
In conclusion, we show that pathogen-specific structures alone
or associated with T cell co-stimulation molecules directly trigger
and control B cell responses. According to the TLR pathway
involved and the activation of BCR signal, the response would be
directed either to memory B cells or to ASC differentiation
resulting in production of mainly polyclonal antibodies. Besides a
better understanding of mouse B cell biology, these observations
made have important implications in vaccination by specifically
designing optimally cooperative antigen/adjuvants combinations
that would specifically activate B cells while limiting the polyclonal
response often responsible for autoimmune diseases [48].
Materials and Methods
Ethics Statement
The research was conducted in accordance with the European
Community guidelines (Directive 86/609/EEC) on the protection
of animals used for scientific purposes. The IBMC animal house
facilities are approved by French veterinary service (#E67-482-2).
As no surgery or experimentation has been done on animals
before euthanasia, we did not need specific ethical approval. Mice
were euthanized according the European Community guidelines
before spleen removing.
Mice
BALB/c and C57BL/6 mice as well as C57BL/6 CD40
knockout mice were bred in IBMC animal house facilities.
Antibodies and reagents
Phycoerythrin (PE)-labeled anti-mouse CD69 (clone H1-2F3),
anti-mouse CD86-PE (clone GL1), anti-mouse CD138-PE (clone
281.2) and allophycocyanin (APC)-labeled anti-mouse B220 (clone
RA3-6B2) monoclonal antibodies (mAbs) were purchased from
PharMingen (BD Biosciences, San Diego, CA). F(ab9)2 fragment
of goat anti-Mouse IgM (referred as anti-IgM in the text) used in
cell culture experiments, goat anti-mouse IgG+IgM (H+L), goat
anti-mouse IgM conjugated to horseradish peroxidase, goat anti-
mouse IgG conjugated to horseradish peroxidase, and mouse IgM
and IgG were purchased from Jackson Immunoresearch (West-
Grove, PA). TLR agonists Pam2CSK4, Pam3CSK4, poly (I:C),
LPS from Escherichia coli (K12), R848 and CpG oligonucleotide
CpG2395 59- TCGTCGTTTTCGGCGCGCGCCG- 39 and
CpG1668 59- TCCATGACGTTCCTGATGCT- 39 were pur-
chased from Invivogen (San Diego, CA). Polymyxin B solution was
purchased from Sigma-Aldrich (Saint-Louis, MO). Recombinant
soluble hFc-mCD40L (referred as mCD40L in the text) was
produced in CHO cells (Sigma-Aldrich) as previously described for
Fc-EDA [49] using amino acids 115–260 of mouse CD40L.
B cell preparation and culture
Primary B cells were purified from spleens of 10- to 12- week-
old mice using a negative selection strategy. Briefly, spleen cells
were depleted from macrophages, granulocytes, CD4+ T cells and
CD8+ T cells by incubation during 20 minutes at 4uC with anti-
CD11b (clone Mac-1), anti-GR1 (clone 8C5), anti-CD4 (clone GK
1.5) and anti-CD8 (clone Lyt-2) mAbs purified in-house. After
Figure 5. Antibody production in purified B cell culture supernatant after activation by TLR agonists in association with mCD40L.
Purified B cells were cultured as described in figure 2 for 6 days. Cell culture supernatants were collected and amounts of IgM (A) and IgG (B) were
measured by ELISA as described in Material and Methods. Results are expressed in mg/mL for IgM and ng/mL for IgG and shown as the means+SD of
three independent experiments. *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0025542.g005
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incubation, magnetic beads coupled to anti-rat Ig (dynal, Oslo,
Norway) were added during 20 minutes at 4uC. The bead-bound
cells were separated by a magnet and discarded. The remaining
cells referred as purified B cells (containing more than 90% B cells
as determined by flow cytometry analysis) were used in all
experiments. Purified B cells were cultured (3.105/well) in 96-well
U-bottom plates in a final volume of 200 mL or (1.15.106/well) in
24-well plates in a final volume of 1150 mL. Cultures were
performed in RPMI 1640 medium (Cambrex, Verviers, Belgium)
supplemented with 10% fetal calf serum (FCS; Lonza, Verviers,
Belgium), 10 mg/mL gentamicin (Cambrex), 10 mM HEPES
(Cambrex) and 0.05 mM 2-mercaptoethanol. Cells were incubat-
ed with mCD40L alone or in association with the various TLR
agonists at the concentrations indicated in the text. In some
experiments, an anti-IgM antibody (1 mg/mL) was added to the
culture simultaneously with TLR agonists and mCD40L. When
used, anti-TLR2 antibody (1 mg/mL) or polymyxin B (20 mg/mL)
were added 20 min before TLR agonists and mCD40L.
Activation and proliferation assays
For measurement of membrane expression of activation
markers by flow cytometry, cells were harvested after 24 h of
culture and labeled with anti-CD69 and anti-CD86 mAb as
described below. For cytokine measurement, supernatants were
collected after 48 h and tested for CCL22/MDC production by
ELISA. To measure cell proliferation, [3H]-thymidine (1 mCi;
specific activity 6.7 Ci/mmol) was added after 64 h of culture, cells
were harvested 8 h later on a filter with an automatic cell-
harvesting device (Packard, Meriden, CT), and thymidine
incorporation was assessed by using a Matrix 9600 direct beta
counter (Packard; cpm range from 10 to 35,000). Data were
expressed as the stimulation index calculated as follows: the mean
counts per minute (cpm) of stimulated cells/the mean cpm of
unstimulated cells. Proliferation experiments were performed in
triplicate.
Markers of plasma cell differentiation, CSR and SHM
To evaluate Blimp-1 mRNA expression in B cell population,
purified B cells were harvested after 72 h of culture and
quantitative real-time PCR (qRT-PCR) was performed as
described below.
To measure IgM and IgG production by ELISA, cell culture
supernatants of purified B cells cultured in 24-well plates were
harvested at day 6.
In some experiments, enrichment in CD138+ cells was
performed. For this, purified B cells were stained after 72 h of
culture with PE-labeled anti-CD138 antibodies for 15 min at 4uC
and further incubated with magnetic microbeads coupled to anti-
PE antibodies, as indicated by the manufacturer (Miltenyi Biotech,
Bergisch, Gladbach, Germany). CD138+-labeled cells were then
selected upon cell loading on a MACS LS column (Miltenyi
Biotech). Enriched CD138+ cells were labeled with anti-CD138
and anti-B220 antibodies before flow cytometry analysis and qRT-
PCR was performed to quantify Blimp-1, Pax-5 and AID mRNAs.
Flow cytometry
Cells were washed in phosphate-buffered saline (PBS) contain-
ing 2% FCS and incubated at 4uC for 20 min with the various
antibodies used at a concentration recommended by the
manufacturer. After two washes in PBS-2% FCS, cells were
analyzed by flow cytometry with a FACSCaliburH and data were
processed with the CellQuest 3.3 software (Becton Dickinson, Pont
de Claix, France).
ELISA assays
Commercially available ELISA reagents were employed for the
determination of CCL22/MDC (QuantikineH, R&D Systems,
Minneapolis, MN). All procedures were performed following the
manufacturer’s instructions. Results were expressed as chemokine
concentration in pg/mL. The detection limit was 1.2 pg/mL.
To measure IgM and IgG in culture supernatants, 96-well plates
were coated with 1 mg/mL goat anti-mouse IgG+IgM (H+L)
antibody overnight at 37uC. The plates were washed and then
blocked with 0.9% BSA in PBS containing 0.05% (v/v) Tween-20
for 60 min at 37uC. Supernatants were diluted in RPMI 1640
medium and added to the plates along with purified mouse IgM or
IgG to establish a standard concentration curve. The plates were
incubated for 60 min at 37uC, then washed, and goat anti-mouse
IgM or IgG conjugated to horseradish peroxidase diluted 1/
20,000 and 1/10,000 respectively in PBS-Tween, were added and
incubated for 30 min at 37uC. The plates were then washed and
the reaction was revealed by addition of 0.04% (v/v) H2O2 and 3,
39, 5, 59-tetramethyl benzidine (3 mg/mL) as chromogen.
Absorbance was measured at 450 nm.
Quantitative real-time PCR
Approximately 3.106 purified B cells or 1.106 enriched CD138+
cells were homogenized with 1 ml of Tri Reagent (Sigma-Aldrich)
and total RNA was purified using RNeasyH Mini Kit (Qiagen,
Germantown, MD). cDNA was synthetized by extension of a mix
of oligo(dT) and random primers with ImProm-IITM reverse
transcriptase (Promega, Fitchburg, WI). The reaction mix was
diluted 1/10 for real time-PCR. Expression of individual
transcripts was normalized according to the mean of the
expression of three different housekeeping genes, namely b-actin,
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and hypo-
xanthine guanine phosphoribosyl transferase (HPRT). Primer
sequences were designed with the Primers3 software (http://
packages.debian.org/org/fr/sid/primer3). All amplification reac-
tions were performed in a total volume of 25 mL using a MxPro-
Mx3005P Thermocycler sequence detector (Stratagene, La Jolla,
CA) with Mesa Green qPCR MasterMix Plus for SYBR Assay
Low ROX (Eurogentec, Seraing, Belgium) according to the
manufacter’s instructions. Data were analysed using the software
toll rest-384-beta-9august2006.
The primer sequences (forward/reverse) used were: mBlimp-1,
59-TTTTACTCAGCTCGCCCACCT-39/39-TTGGCAGGGC-
ACACCTTACA-59, mPax-5, 59-GCCCACAGTCCTACCCTA-
TTG-39/39-GAGGGTGGCTGTAGGGACTT-59 mAID, 59-G-
GGAGTCAAGAAAGTCACGC-39/39-CTGCCGTACTCTGG-
ATGGAG-59, mGAPDH, 59-TGACGTGCCGCCTGGAGAAA-
39/39-AGTGTAGCCCAAGATGCCCTTCAG-59, mb-actin, 59-
ATGAGCTGCCTGACGGCCAGGTCATC -39/39-TGGTAC-
CACCAGACAGCACTGTGTTG-59, mHPR, 59-CTTGCTG-
GTGAAAAGGACCTCT-39/39-AAGTACTCATTATAGTCA-
AGGGCAT-5.
Statistical analysis
Proliferation assay, activation markers expression, CCL22, IgG
and IgG production in the presence or not of mCD40L were
analyzed by two-way ANOVA with Bonferroni’s post test using
GraphPad Prism version 5.00 for Windows, GraphPad Software,
San Diego California USA, www.graphpad.com. For quantitative
real-time PCR analysis, the investigated transcripts are tested for
significance by a pair wise fixed reallocation randomisation test .
P,0.001 ***, P,0.01 **, P,0.05 *, P.0.05 ns.
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Supporting Information
Figure S1 Proliferative response of mouse spleen B cells
induced by TLR agonists. (A) Purified B cells from C57/BL6
CD40 deficient or wt mice were cultured in the presence of
TLR1/2 agonist Pam3CSK4 (250 ng/mL), TLR2/6 agonist
Pam2CSK4 (50 ng/mL), TLR3 agonist poly (I:C) (10 mg/mL),
TLR4 agonist LPS (10 mg/mL), TLR7 agonist R848 (1 mg/mL) or
TLR9 agonist ODN 2395 (200 nM) alone or in the presence of
0.6 mg/mL mCD40L. (B) Purified B cells from BALB/c wt mice
were cultured in the presence of TLR3 agonist poly (I:C) (50 mg/
mL) and TLR4 agonist LPS (10 mg/mL) alone or in the presence
of 0.6 mg/mL mCD40L, with or without Polymixin (20 mg/mL).
Results are representative of at least two independent experiments.
(TIF)
Figure S2 Mouse spleen B cell expression of BLIMP-1
mRNA. (A) Total RNA was isolated from purified B cells from
C57/BL6 CD40 deficient or wt mice cultured for 72 h with
TLR1/2 agonist Pam3CSK4 (250 ng/mL), TLR2/6 agonist
Pam2CSK4 (50 ng/mL) and TLR7 agonist R848 (1 mg/mL)
alone or in the presence of 0.6 mg/mL mCD40L. (B) Total RNA
was isolated from purified B cells from BALB/c wt mice cultured
for 72 h with TLR1/2 agonist Pam3CSK4 (250 ng/mL) and
TLR2/6 agonist Pam2CSK4 (50 ng/mL) alone or in the presence
of 0.6 mg/mL mCD40L, with or without antagonistic anti-TLR2
antibody. (C) Total RNA was isolated from purified B cells from
BALB/c wt mice cultured for 72 h with TLR4 agonist LPS
(10 mg/mL) alone or in the presence of 0.6 mg/mL mCD40L, with
or without Polymixin (20 mg/mL). (D) Total RNA was isolated
from purified B cells from BALB/c wt mice cultured for 72 h with
TLR9 agonist type B (ODN1668) alone or in the presence of
0.6 mg/mL mCD40L. Results are representative of at least two
independent experiments.
(TIF)
Figure S3 CD138 enriched mouse spleen B cell expres-
sion of BLIMP-1 and PAX-5 mRNA. Purified B cells were
cultured with TLR2/6 agonist Pam2CSK4 (50 ng/mL), TLR1/2
agonist Pam3CSK4 (250 ng/mL), TLR3 agonist poly (I:C)
(10 mg/mL), TLR4 agonist LPS (10 mg/mL), TLR7 agonist
R848 (1 mg/mL) or TLR9 agonist ODN 2395 (200 nM) alone
or in the presence of 0.6 mg/mL mCD40L. After 72 h, population
was enriched in CD138 positive cells as described in Material and
Methods. Total RNA was isolated and expression of BLIMP-1 (A)
or PAX-5 (B) transcripts were evaluated by quantitative real-time
PCR. Results are expressed as the fold induction of gene
transcription as compared to the CD138-enriched purified B cells
cultured in medium. *p,0.05, **p,0.01, ***p,0,001 Results are
representative of at least three independent experiments.
(TIF)
Figure S4 Differentiation on mouse B spleen cells in
ASC. Purified B cells were cultured with TLR2/6 agonist
Pam2CSK4 (50 ng/mL), TLR1/2 agonist Pam3CSK4 (250 ng/
mL), TLR3 agonist poly (I:C) (10 mg/mL), TLR4 agonist LPS
(10 mg/mL), TLR7 agonist R848 (1 mg/mL) or TLR9 agonist
ODN 2395 (200 nM) alone or in the presence of 0.6 mg/mL
mCD40L. After 72 h, population was enriched in CD138 positive
cells as described in Material and Methods. CD138-enriched
purified B cells were then co-stained with anti-B220 and anti-
CD138 antibodies and the expression of these markers was
determined by flow cytometry.
(TIF)
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